Copy to clipboard 
Seikagaku posted FY 3Q18 revenue of ¥7,330MM (USD $64.7MM), -11.1% vs. FY 3Q17, as the company continues to deal with the impact from reduced drug prices as mandated by the NHI in Japan. The price reduction has filtered through to bottom line earnings as Seikagaku was able to lower administrative and general expenses, but still experienced reduced operating income due to the revenue shortfall.
Despite observing an overall orthobiologic market contraction on a volume basis, the company was able to increase deliveries of their ARTZ product, though this was not sufficient to offset the impact of price reductions. HERNICORE, launched in August 2018, is in a phased roll out and has not yet significantly contributed to sales. The condoliase-based injectable product is indicated to treat lumbar disc herniation.
Globally, Seikagaku is facing an increasingly difficult U.S. market through increased competition and tightening insurance reimbursement requirements. Sales of Gel-One single-injection hyaluronic acid treatment increased, but were offset by price erosion and shipments delayed into 4Q. SUPARTZ FX, a five-injection treatment, declined sharply due to increased reimbursement requirements. In China, however, ARTZ sales increased due to sales partner expansion in both urban and rural areas.
The company provided full fiscal year 2018 guidance of ¥28,100MM ($258.6MM), -6.9% vs. FY 2017.
Sales and growth on an as-reported basis are as follows. The company’s fiscal year 2018 runs from April 1, 2018 through March 31, 2019.
| 3Q18 | 3Q17 | $ Change | % Change | |
| Orthobiologics | $64.7 | $72.8 | -$8.1 | -11.1% |
| 9Mo18 | 9Mo17 | $ Change | % Change | |
| Orthobiologics | $198.7 | $215.4 | -$16.7 | -7.8% |
Source: Seikagaku
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Seikagaku posted FY 3Q18 revenue of ¥7,330MM (USD $64.7MM), -11.1% vs. FY 3Q17, as the company continues to deal with the impact from reduced drug prices as mandated by the NHI in Japan. The price reduction has filtered through to bottom line earnings as Seikagaku was able to lower administrative and general expenses, but still experienced...
Seikagaku posted FY 3Q18 revenue of ¥7,330MM (USD $64.7MM), -11.1% vs. FY 3Q17, as the company continues to deal with the impact from reduced drug prices as mandated by the NHI in Japan. The price reduction has filtered through to bottom line earnings as Seikagaku was able to lower administrative and general expenses, but still experienced reduced operating income due to the revenue shortfall.
Despite observing an overall orthobiologic market contraction on a volume basis, the company was able to increase deliveries of their ARTZ product, though this was not sufficient to offset the impact of price reductions. HERNICORE, launched in August 2018, is in a phased roll out and has not yet significantly contributed to sales. The condoliase-based injectable product is indicated to treat lumbar disc herniation.
Globally, Seikagaku is facing an increasingly difficult U.S. market through increased competition and tightening insurance reimbursement requirements. Sales of Gel-One single-injection hyaluronic acid treatment increased, but were offset by price erosion and shipments delayed into 4Q. SUPARTZ FX, a five-injection treatment, declined sharply due to increased reimbursement requirements. In China, however, ARTZ sales increased due to sales partner expansion in both urban and rural areas.
The company provided full fiscal year 2018 guidance of ¥28,100MM ($258.6MM), -6.9% vs. FY 2017.
Sales and growth on an as-reported basis are as follows. The company’s fiscal year 2018 runs from April 1, 2018 through March 31, 2019.
| 3Q18 | 3Q17 | $ Change | % Change | |
| Orthobiologics | $64.7 | $72.8 | -$8.1 | -11.1% |
| 9Mo18 | 9Mo17 | $ Change | % Change | |
| Orthobiologics | $198.7 | $215.4 | -$16.7 | -7.8% |
Source: Seikagaku
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
